Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Core Viewpoint - Palisade Bio, Inc. has appointed Dr. James Izanec as Vice President of Clinical Development, bringing extensive experience in leading global Phase 2/3 programs in immunology, neurology, and gastroenterology [1][3][4] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases [8][10] - The lead program, PALI-2108, targets moderate-to-severe Ulcerative Colitis (UC) and Fibrostenotic Crohn's Disease (FSCD), with a recent Phase 1b trial showing a 100% clinical response in the UC cohort [10][11] Leadership and Experience - Dr. Izanec has over two decades of experience in clinical and drug development, having previously held senior roles at Bristol Myers Squibb and Janssen [3][4][5] - His background includes overseeing a 1,200-patient Phase 3 Crohn's program and leading pediatric development programs in related diseases [4][5] Clinical Development Strategy - The company is advancing PALI-2108 towards a Phase 2 clinical study in UC, focusing on clinical remission, response, and pharmacodynamic biomarkers over 12 weeks [11] - Plans are also in place to initiate studies in FSCD to further evaluate PALI-2108's safety and therapeutic benefits [11]